Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

The mouse to human conversion is not 1:1. It has been discussed many times here. I guess Dr. Menon's expected efficacy range of 100-200 mg/m2, a reported tumor regression case at Biotech Showcase 2014, and the spleen lesion disappearance case means nothing to some people.

Why the higher dose cohorts matter: Look back at the original poster presentation for K, at the solid tumor dosing required for effect. You will see that compared to other chemo agents, K needs MUCH higher concentrations to kill the same amnt of multiple solid tumor cell line types.(I am not calling K chemo) Thus the fact that the drug is well tolerated is probably very much in our favor, because patients will likely need to get a lot of K for it to work(vs other standard agents)